September 12, 2022 | Berlin, Germany and Brussels, Belgium
Eckert & Ziegler Eurotope GmbH (Eckert & Ziegler) and Precirix NV have signed a collaboration agreement for the development of a highly reliable and efficient automated production process for Precirix’ 68Ga based diagnostic tools. Using Eckert & Ziegler’s synthesis equipment and quality control platforms, the designed process shall enable the use of Precirix’ compounds for patient selection in international clinical studies, in line with Precirix’ theranostic approach for development of its radiotherapeutic drug candidates.
Precirix develops radiopharmaceuticals using camelid single domain antibody fragments. The company’s technology platform allows for a theranostic approach, using the same molecule for imaging diagnostics and therapy.
“We look forward to working with Eckert & Ziegler to benefit from their competence in radiosynthesis design and devices. After the successful process development for automated 68Ga labeling, we intend to establish a standardized clinical environment that combines our tracers with Eckert & Ziegler’s equipment to make it available to nuclear medicine centers worldwide,” said Dr. Dimitrios Mantzilas, Chief Technology Officer at Precirix.
“The collaboration with Precirix once again emphasizes our commitment to making radiopharmaceuticals available for a wide variety of diagnostic and therapeutic applications. We are pleased to support Precirix’ promising platform with our expertise in the clinical phase and beyond.”, added Dr. Sven-Peter Heyn, general manager of Eckert & Ziegler Eurotope GmbH.
Eckert & Ziegler and Precirix will both participate in the Annual Congress of the European Association of Nuclear Medicine (EANM22) in Barcelona, Spain from October 15 – 19, 2022. Precirix will provide insights into its platform and the collaboration during Eckert & Ziegler’s satellite symposium on “Theranostic Innovations in solid and non-solid tumors targeting CXCR4, HER2, FAP, αvβ6 & more” on October 18 from 13:15 – 14:45.
About Precirix
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a therapeutic dose for treatment.
Contact
Precirix NV
Ruth Devenyns, CEO
+32 2 479 93 60, info@precirix.com, www.precirix.com
About Eckert & Ziegler Eurotope GmbH
Eurotope GmbH belongs to the Eckert & Ziegler group and represents the Lab Devices business unit of the Medical Segment. The company develops, manufactures and sells systems and accessories for radionuclide labeling and quality control of radiopharmaceuticals. The products are used in research and routine manufacturing of patient doses for cancer diagnosis and therapy in hospitals as well as in industrial manufacturing processes for radioactively labeled compounds and drugs.
As part of the Medical Segment, Eurotope GmbH contributes to provide complete solutions to Eckert & Ziegler´s worldwide customers in the nuclear medicine and pharma industry. The comprehensive product and service portfolio of Medical’s One-Stop-Shop ranges from customized hot cell solutions and in-cell equipment over radionuclides to contract development and GMP-manufacturing services for radiopharmaceuticals through all stages from early clinical to commercial supply.
Contact
Eckert & Ziegler Eurotope GmbH
Jan Schöpflin, Head of Marketing
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-0, marketing.medical@ezag.de, www.medical.ezag.com